Cargando…

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting

An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coplan, PM, Chilcoat, HD, Butler, SF, Sellers, EM, Kadakia, A, Harikrishnan, V, Haddox, JD, Dart, RC
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102571/ https://www.ncbi.nlm.nih.gov/pubmed/27170195 http://dx.doi.org/10.1002/cpt.390

Ejemplares similares

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
por: Janoff, Shannon L., et al.
Publicado: (2016)

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse
por: McNaughton, Emily C, et al.
Publicado: (2014)

The controversy surrounding OxyContin abuse: issues and solutions
por: Jayawant, Sujata S, et al.
Publicado: (2005)

An overview of abuse-deterrent opioids and recommendations for practical patient care
por: Adler, Jeremy A, et al.
Publicado: (2018)

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology
por: Dasgupta, Nabarun, et al.
Publicado: (2021)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance
por: Zhao, Liang, et al.
Publicado: (2021)

Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin(®) Tablets Compared with Original OxyContin(®) Tablets in Healthy Adults
por: Perrino, Peter J., et al.
Publicado: (2013)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020)

Pattern of buprenorphine abuse among opioid abusers in Nepal
por: Aich, Tapas Kumar, et al.
Publicado: (2010)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

OxyContin and the McDonaldization of chronic pain therapy in the USA
por: Hughes, Jordan, et al.
Publicado: (2019)

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
por: L. Keast, Shellie, et al.
Publicado: (2016)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

How to prevent opioid abuse and addiction
por: Hwang, Sung Mi
Publicado: (2023)

An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose
por: Beachler, Daniel C., et al.
Publicado: (2022)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era
por: Green, Traci C, et al.
Publicado: (2015)

Effect of opioid dependence or abuse on opioid utilization after shoulder arthroplasty
por: Berglund, Derek D, et al.
Publicado: (2018)

Hepatitis Infection in the Treatment of Opioid Dependence and Abuse
por: Kresina, Thomas F, et al.
Publicado: (2008)

Prescription opioid abuse: pharmacists’ perspective and response
por: Cochran, Gerald, et al.
Publicado: (2016)

Epigenetic Modulation of Opioid Receptors by Drugs of Abuse
por: Reid, Ke Zhang, et al.
Publicado: (2022)

Economic Burden of Prescription Opioid Misuse and Abuse
por: Strassels, Scott
Publicado: (2009)

Modeling Opioid Abuse: A Case Study of the Opioid Crisis in New England
por: Butler, Cole, et al.
Publicado: (2023)

Comparison of Early Maladaptive Schemas and Parenting Origins in Patients with Opioid Abuse and Non-Abusers
por: Jalali, Mohammad Reza, et al.
Publicado: (2011)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
por: Fudin, Jeffrey, et al.
Publicado: (2016)

Prevalence of Narcotic Bowel Syndrome in Opioid Abusers in Iran
por: Ahmadi, Bizhan, et al.
Publicado: (2014)

Development and preliminary validation of the Opioid Abuse Risk Screener
por: Henrie-Barrus, Patricia, et al.
Publicado: (2016)

The rising tide of opioid use and abuse: the role of the anesthesiologist
por: Koepke, Elena J., et al.
Publicado: (2018)

Cost of opioid medication abuse with and without tampering in the USA
por: Vietri, Jeffrey, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ordeoqh75l1ravp8uqmgv389o0